Market Indices
Sector Heatmap
DXD — ProShares UltraShort Dow 30
NYSE ArcaProShares UltraShort Dow 30
- O
- 17.88
- H
- 18.14
- L
- 17.84
- V
- 4.2M
DXD — Latest News & Headlines
16 StoriesFDA Application Withdrawn for I-DXd in Small Cell Lung Cancer - Targeted Oncology
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer Targeted Oncology
Behavioral Patterns of DXD and Institutional Flows - Stock Traders Daily
Behavioral Patterns of DXD and Institutional Flows Stock Traders Daily
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer - Managed Healthcare Executive
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer Managed Healthcare Executive
Oncology Experts Call for Less Toxic Care, Smarter Access - AJMC
Oncology Experts Call for Less Toxic Care, Smarter Access AJMC
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics - Pharmaceutical Executive
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics Pharmaceutical Executive
AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer - stocktitan.net
AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer stocktitan.net
REG - AstraZeneca PLC - AZ & DS collaboration with Summit for Datroway - TradingView
REG - AstraZeneca PLC - AZ & DS collaboration with Summit for Datroway TradingView
Merck (MRK) Withdraws I-DXd Biologics License Application for ES-SCLC - gurufocus.com
Merck (MRK) Withdraws I-DXd Biologics License Application for ES-SCLC gurufocus.com
SA analyst: Yields could soon ‘roll over’ as stocks rally - Seeking Alpha
SA analyst: Yields could soon ‘roll over’ as stocks rally Seeking Alpha
AstraZeneca (AZN) Receives a Buy from RBC Capital - The Globe and Mail
AstraZeneca (AZN) Receives a Buy from RBC Capital The Globe and Mail
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer Drug - Merck & Co (NYSE:MRK) - Benzinga
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer Drug - Merck & Co (NYSE:MRK) Benzinga
Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling. - stocktitan.net
Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling. stocktitan.net
Stocks climb as Hormuz talks turn technical and oil slides - Seeking Alpha
Stocks climb as Hormuz talks turn technical and oil slides Seeking Alpha
AI stocks pull far ahead of global benchmarks - Seeking Alpha
AI stocks pull far ahead of global benchmarks Seeking Alpha
SA analyst sees stocks, bonds, gold, and crypto rising into year-end - Seeking Alpha
SA analyst sees stocks, bonds, gold, and crypto rising into year-end Seeking Alpha
SA analyst warns that tech stocks could join the market selloff - Seeking Alpha
SA analyst warns that tech stocks could join the market selloff Seeking Alpha